These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24229448)

  • 1. The high cost of celiac disease in an Israeli Health Maintenance Organization.
    Heymann AD; Leshno M; Endevelt R; Shamir R
    Health Econ Rev; 2013 Nov; 3(1):23. PubMed ID: 24229448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of serologic testing for celiac disease in asymptomatic patients: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2011; 11(3):1-63. PubMed ID: 23074415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
    Laliberté F; Bookhart BK; Vekeman F; Corral M; Duh MS; Bailey RA; Piech CT; Lefebvre P
    J Manag Care Pharm; 2009 May; 15(4):312-22. PubMed ID: 19422271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
    Margolis J; Barron JJ; Grochulski WD
    J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic benefits of increased diagnosis of celiac disease in a national managed care population in the United States.
    Green PH; Neugut AI; Naiyer AJ; Edwards ZC; Gabinelle S; Chinburapa V
    J Insur Med; 2008; 40(3-4):218-28. PubMed ID: 19317331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The direct medical cost of cardiovascular diseases, hypertension, diabetes, cancer, pregnancy and female infertility in a large HMO in Israel.
    Chodick G; Porath A; Alapi H; Sella T; Flash S; Wood F; Shalev V
    Health Policy; 2010 May; 95(2-3):271-6. PubMed ID: 20061044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patients.
    Desai PR; Lawson KA; Barner JC; Rascati KL
    J Manag Care Pharm; 2013; 19(6):468-77. PubMed ID: 23806061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world health plan claims analysis of differences in healthcare utilization and total cost in patients suffering from cluster headaches and those without headache-related conditions.
    Polson M; Lord TC; Evangelatos TM; Lopes M; Santaniello BL
    Am J Manag Care; 2017 Nov; 23(16 Suppl):S295-S299. PubMed ID: 29144719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-related and all-cause health care costs of elderly patients with gout.
    Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
    J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
    Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
    J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of Managing Patients with Diabetes in a Large Health Maintenance Organization in Israel: A Retrospective Cohort Study.
    Porath A; Fund N; Maor Y
    Diabetes Ther; 2017 Feb; 8(1):167-176. PubMed ID: 27853980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the unit costs of public hospitals and primary healthcare centers.
    Younis MZ; Jaber S; Mawson AR; Hartmann M
    Int J Health Plann Manage; 2013; 28(4):320-32. PubMed ID: 23125096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yield and cost of performing screening tests for constipation in children.
    Chogle A; Saps M
    Can J Gastroenterol; 2013 Dec; 27(12):e35-8. PubMed ID: 24228262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actuarial analysis of private payer administrative claims data for women with endometriosis.
    Mirkin D; Murphy-Barron C; Iwasaki K
    J Manag Care Pharm; 2007 Apr; 13(3):262-72. PubMed ID: 17407392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.
    Tencer T; Friedman HS; Li-McLeod J; Johnson K
    J Manag Care Pharm; 2007; 13(9):790-8. PubMed ID: 18062730
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.